Nautilus Biotech

company

About

Nautilus Biotech is a clinical-stage biopharmaceutical company focused on developing therapeutic proteins.

  • 11 - 50

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
€7.25M
Industries
Biopharma,Biotechnology,Therapeutics
Founded date
Jan 1, 1999
Number Of Employee
11 - 50
Operating Status
Active

Nautilus Biotech is a biotechnology company. The company has a pipeline of therapeutic proteins with improved profiles. The company's products include Belerofon, an injectable and orally available interferon alpha for use in the treatment of chronic Hepatitis C infection; and Vitatropin, an injectable and orally available human growth hormone (hGH) for use in the treatment of growth deficiencies. Nautilus Biotech S.A. sells therapeutic proteins, including interferons, hormones, growth factors, and enzymes in France and internationally. The company's protein engineering technology improves the pharmacology profile and administration route of blockbuster protein drugs. Nautilus Biotech S.A. was founded in 1999 and is based in Evry, France.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€7.25M $11.30M
Nautilus Biotech has raised a total of €7.25M $11.30M in funding over 2 rounds. Their latest funding was raised on Apr 30, 2007 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 30, 2007 Series Unknown $11.30M 1 Detail
Mar 3, 2005 Series Unknown €7.25M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Nautilus Biotech is funded by 1 investors. Matignon Investissement & Gestion are the most recent investors.
Investor Name Lead Investor Funding Round
Matignon Investissement & Gestion Series Unknown